Axsome Therapeutics Inc. on Tuesday said it plans to file for U.S. Food and Drug Administration approval of AXS-14 for the management of fibromyalgia by the end of next year.
The New York biopharmaceutical company said a pair of placebo-controlled trials have shown the potential for AXS-14 to improve the symptoms of the debilitating central-nervous-system condition, which currently has limited treatment options.
Axsome said it plans to submit a new drug application for AXS-14 in the fourth quarter of 2022, pending successful completion of manufacturing and other activities related to the product candidate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.